STAT+: Pharmalittle: U.S. government blunder contributed to monkeypox vax shortage; Amgen to pay $4 billion for ChemoCentryx
Amgen will acquire ChemoCentryx for $4 billion to obtain a newly approved medicine that treats patients with a serious autoimmune condition.
Top of the morning to you. Another steamy day is unfolding here at the Pharmalot campus, where the short person will soon leave
